JNJ-26854165 is one of p53-activating agents and synergizes with AraC or doxorubicin to induce p53-mediated apoptosis and may provide a novel therapeutic approach for the treatment of acute leukemias.
More Information Supplier PageJNJ-26854165 is one of p53-activating agents and synergizes with AraC or doxorubicin to induce p53-mediated apoptosis and may provide a novel therapeutic approach for the treatment of acute leukemias.
More Information Supplier PageIsotretinoin was developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more.
More Information Supplier PageIsotretinoin was developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more.
More Information Supplier PageIsotretinoin was developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more.
More Information Supplier PageIsotretinoin was developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more.
More Information Supplier PageIsotretinoin was developed to be used as a chemotherapy medication for the treatment of brain cancer, pancreatic cancer and more.
More Information Supplier PageIsoprenaline or isoproterenol is a non-selective beta-adrenergic agonist and structurally similar to adrenaline.
More Information Supplier PageIsoprenaline or isoproterenol is a non-selective beta-adrenergic agonist and structurally similar to adrenaline.
More Information Supplier Page
